B7-H7
Broad impact.
Precision Therapeutics.
Our Science
NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing a T-cell engager engineered with superior therapeutic index, an antibody-drug-conjugate with our proprietary linker technology, and a multi-functional checkpoint inhibitor.
LEARN ABOUT OUR SCIENCE
Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed modality, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation including those who do not benefit from currently approved therapies such as PD-1/L1 inhibitors.
Our Pipeline
A unified pipeline to create precision therapeutics that combine direct tumor cell killing and immunomodulation in each single molecule for long-term cancer control, featuring first-in-class assets backed by a strong IP position.
LEARN ABOUT OUR PIPELINE
Our Team
World-class Team
We are building a world-class team to help us realize the full potential of our scientific founders’ exciting discoveries and to shape the future of immuno-oncology and tumor-targeting
LEARN ABOUT US
LEARN ABOUT US
Careers
VIEW OPEN POSITIONS
SEND US YOUR RESUME